All Posts by Date or last 15, 30, 90 or 180 days.
As an Amazon Associate I earn from qualifying purchases @AMAZON

Designed for the most demanding needs of photographers and videographers.
Connect and charge all of your devices through a single Thunderbolt or USB-C port.

WSJ: Ivermectin Didn’t Reduce Covid-19 Hospitalizations in Largest Trial to Date + FLCCC Rebuttal

Was this a trial designed to fail, as so many are when Big Pharma wants it to?

See the rebuttal from the Critical Care Alliance, but how is the average person (or even doctors!) to know who is credible and who is not?

WSJ: Ivermectin Didn’t Reduce Covid-19 Hospitalizations in Largest Trial to Date

2022-04-01. Emphasis added.

Patients who got the antiparasitic drug didn’t fare better than those who received a placebo

Researchers testing repurposed drugs against Covid-19 found that ivermectin didn’t reduce hospital admissions, in the largest trial yet of the effect of the antiparasitic on the disease driving the pandemic.

Ivermectin has received a lot of attention as a potential treatment for Covid-19 including from celebrities such as podcast host Joe Rogan. Most evidence has shown it to be ineffective against Covid-19 or has relied on data of poor quality, infectious-disease researchers said. Public-health authorities and researchers have for months said the drug hasn’t shown any benefit in treating the disease. Taking large doses of the drug is dangerous, the Food and Drug Administration has said. 

The latest trial, of nearly 1,400 Covid-19 patients at risk of severe disease, is the largest to show that those who received ivermectin as a treatment didn’t fare better than those who received a placebo.

“There was no indication that ivermectin is clinically useful,” said Edward Mills, one of the study’s lead researchers and a professor of health sciences at Canada’s McMaster University in Hamilton, Ontario. Dr. Mills on Friday plans to present the findings, which have been accepted for publication in a major peer-reviewed medical journal, at a public forum sponsored by the National Institutes of Health.

...

WIND: and the Front Line Critical Care Alliance, which has actually been treating patients (!) for a lengthy period of time, responds. Emphasis added.

FLCCC Responds to Wall Street Journal Article on Results of TOGETHER TRIAL

On March 18, 2022, The Wall Street Journal published an article entitled: ‘Ivermectin Didn’t Reduce Covid-19 Hospitalizations in Largest Trial to Date’.

The results of this trial, which was predetermined to show ivermectin as ineffective, affirms the need for early treatment against COVID-19 and confirms that conflicted groups continue to influence competitor trials, ensuring they are designed to fail. Several organizations associated with the trial have a paid client relationship with Pfizer, which has secured Federal government contracts worth $5.3 billion for its antiviral treatment, Paxlovid. A full list of trial sponsors and associates can be found here.

It is therefore no surprise that the trial was designed to fail. In the medical community, it is common knowledge that COVID-19 becomes far more difficult to treat the longer a patient has had symptoms. Treating early is imperative. Yet the TOGETHER trial studied patients where they started treatment up to eight days after the onset of symptoms.

Furthermore, no qualified physician or scientist recommends treating COVID-19 with the low dosage of ivermectin used in the trial, nor treating a patient with ivermectin for only three days on an empty stomach, as TOGETHER did. FLCCC physicians have understood for nearly 18 months that ivermectin works best against COVID-19 when administered with a fatty meal and until symptoms resolve.

Our frontline physicians – who were treating COVID-19 with corticosteroids months before the NIH recommended them – have found ivermectin is most effective as part of a treatment protocol that includes other FDA-approved medications and supplements backed by clinical and observational evidence. The use of our I-MASK+, MATH+ and I-RECOVER protocols have all been proven to be effective at corresponding stages of the illness.

Trials of generic medicines that are funded and influenced by profit-driven pharmaceutical companies will always fail. We need to create an independent, well-funded government body dedicated to conducting well-designed trials and transparent research studies of repurposed generic treatments – not only for COVID-19, but for all diseases that may have safe and affordable remedies. The use of independent research is our only hope of understanding how these medicines can best be used to help patients.

WIND: I cannot take any trial funded by Big Pharma very seriously, particularly one that avoids the claimed optimal treatment protocol.

View all handpicked deals...

Nikon Z7 II Mirrorless Camera
$2997 $2997
SAVE $click

diglloyd.com | Terms of Use | PRIVACY POLICY
Contact | About Lloyd Chambers | Consulting | Photo Tours
Mailing Lists | RSS Feeds | X.com/diglloyd
Copyright © 2020 diglloyd Inc, all rights reserved.
Display info: __RETINA_INFO_STATUS__